Posted in | News | Nanomaterials | Nanobusiness

NanoLogix Recently Filed BioNanoPore Patent Applications in China, Japan, India, Brazil, Russia and the EU

NanoLogix, Inc. (PINKSHEETS: NNLX) announces that the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU. These applications were filed in order to obtain intellectual property protection for the company's technology in countries viewed as representing the largest potential international market for BNP rapid detection, a revolutionary sandwiched-membrane Petri-based technology that can reduce microorganism detection times by 100-400%.

At the company's September 25th shareholder meeting, the support for all proposals presented by the company for shareholder approval was overwhelmingly positive, with all shareholder-rights/takeover-defense plan proposals receiving 98-99% of the 64 million shares voted out of roughly 101 million shares outstanding.

The company has reclaimed full rights to 18 patents previously licensed to Nutra Pharma Corporation after failure of Nutra Pharma to pay the balance of patent royalties due for 2008 and the first half of 2009. Nutra Pharma was served notice of their default in July. NanoLogix has returned the 18 patents to the company portfolio and will pursue development and marketing of select technological aspects of the patents.

NanoLogix's April press release: "New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague," was highlighted in the latest issue of the Department of Defense Quarterly, "CBRNIAC," from the Chemical, Biological, Radiological and Nuclear Defense Information Analysis Center. The publication can be accessed at: https://www.cbrniac.apgea.army.mil/Products/Newsletter/Pages/default.aspx

NanoLogix has received notification from New Brunswick Scientific of a November 20th shipping date for ordered production equipment for its cleanroom production facility at the company's Hubbard, Ohio headquarters. This order consists of four machines for production of BNP rapid-detection kits and is anticipated to be the first of many for kit production.

NanoLogix management, staff, and directors would like to congratulate Corporate Counsel David R. Barnhizer for his recent three-year appointment as Visiting Professor to the University of Westminster, London. Professor Barnhizer will continue as corporate counsel.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoLogix. (2019, March 18). NanoLogix Recently Filed BioNanoPore Patent Applications in China, Japan, India, Brazil, Russia and the EU. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=14477.

  • MLA

    NanoLogix. "NanoLogix Recently Filed BioNanoPore Patent Applications in China, Japan, India, Brazil, Russia and the EU". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=14477>.

  • Chicago

    NanoLogix. "NanoLogix Recently Filed BioNanoPore Patent Applications in China, Japan, India, Brazil, Russia and the EU". AZoNano. https://www.azonano.com/news.aspx?newsID=14477. (accessed November 21, 2024).

  • Harvard

    NanoLogix. 2019. NanoLogix Recently Filed BioNanoPore Patent Applications in China, Japan, India, Brazil, Russia and the EU. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=14477.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.